Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Rachel B. Salit, MD, Michael R. Bishop, MD, Steven Z. Pavletic, MD, Frances T. Hakim, PhD, Seth M. Steinberg, PhD, Jeanne Odom, RN, Kelly Bryant, RN, Jennifer Wilder, RN, Daniele N. Avila, CRNP, Bazetta Blacklock-Schuver, RN, Ronald E. Gress, MD, Daniel H. Fowler, MD

Blood (2011) 118 (21): 1937.

https://doi.org/10.1182/blood.V118.21.1937.1937

Published: 2011

Journal Articles

Targeted Lymphocyte Depletion: A Personalized Approach to Achieve Rapid Complete Donor Chimerism and Enhance Graft-Versus-Tumor Effects Following Reduced Intensity Allogeneic Stem Cell Transplantation for High-Risk Hematologic Malignancies.

Rachel B. Salit, MD, Seth Steinberg, PhD, Daniel H. Fowler, MD, Jeanne Odom, RN, Kelly Bryant, RN, Michael R. Bishop, MD

Blood (2009) 114 (22): 656.

https://doi.org/10.1182/blood.V114.22.656.656

Published: 2009

Journal Articles

Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment.

Rachel B. Salit, MD, Seth Steinberg, PhD, Daniel H. Fowler, Jeanne Odom, RN, Kelly Bryant, RN, Michael R. Bishop, MD

Blood (2009) 114 (22): 865.

https://doi.org/10.1182/blood.V114.22.865.865

Published: 2009

Journal Articles

EPOCH-F: A Novel Salvage Regimen for Multiple Myeloma Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation

Saad Jamshed, MD, Daniel Fowler, MD, Sattva Neelapu, MD, Robert M. Dean, MD, Seth M Steinberg, PhD, Jeanne Odom, RN, Kelly Snow, RN, Ronald E Gress, MD, Michael R Bishop, MD

Blood (2008) 112 (11): 4328.

https://doi.org/10.1182/blood.V112.11.4328.4328

Published: 2008

Journal Articles

Burden of Illness in Chronic Graft vs. Host Disease - A Prospective Cohort Study.

Iskra Pusic, MD, John Dickinson, MD, PhD, Seth Steinberg, PhD, Jeanne Odom, RN, Niveen Atlam, Sandra Mitchell, RN, NP, Daniele Avila, RN, NP, Michael Krumlauf, RN, Kristin Baird, MD, Steven Pavletic, MD

Blood (2007) 110 (11): 1667.

https://doi.org/10.1182/blood.V110.11.1667.1667

Published: 2007

Journal Articles

Elevated Serum Interleukin-7 Levels Precede the Development of Acute Graft-Versus-Host Disease.

Robert M. Dean, MD, Terry Fry, MD, Crystal Mackall, MD, Seth M. Steinberg, PhD, Frances T. Hakim, PhD, Daniel H. Fowler, MD, Jeanne Odom, RN, Jason Foley, MS, Ronald E. Gress, MD, Michael R. Bishop, MD

Blood (2007) 110 (11): 1064.

https://doi.org/10.1182/blood.V110.11.1064.1064

Published: 2007

Journal Articles

Safety and Efficacy of Cytotoxic Chemotherapy after Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Hematologic Malignancy.

Nancy M. Hardy, MD, Jeanne Odom, RN, Kelly Snow, RN, Robert Dean, MD, Steven Pavletic, MD, Claude Sportes, MD, Ronald Gress, MD, Daniel H. Fowler, MD, Michael R. Bishop, MD

Blood (2006) 108 (11): 5333.

https://doi.org/10.1182/blood.V108.11.5333.5333

Published: 2006

Journal Articles

Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).

Robert M. Dean, MD, Daniel Fowler, MD, Wyndham H. Wilson, MD, PhD, Frances Hakim, PhD, Seth Steinberg, PhD, Jeanne Odom, RN, Catherine Chow, MD, Claude Sportes, MD, Juan Gea-Banacloche, MD, Steven Z. Pavletic, MD, Nancy M. Hardy, MD, Ronald Gress, MD, Michael R. Bishop

Blood (2006) 108 (11): 317.

https://doi.org/10.1182/blood.V108.11.317.317

Published: 2006

Journal Articles

Allograft T Cell Content Influences Early Engraftment after Reduced-Intensity Stem Cell Transplantation (RIST).

Robert M. Dean, MD, Daniel H. Fowler, MD, Nancy M. Hardy, MD, Jeanne Odom, RN, Kathleen Castro, MSN, Michael Krumlauf, RN, Frances T. Hakim, PhD, Claude Sportes, MD, Ronald E. Gress, MD, Michael R. Bishop

Blood (2005) 106 (11): 3662.

https://doi.org/10.1182/blood.V106.11.3662.3662

Published: 2005

Journal Articles

Increased Expression of Activating Receptors on NK Cells in the Post-Transplant Period.

Michael Boyiadzis, MD, Jesse M. Carson, Sarfraz A. Memon, MD, Robert Dean, MD, Kate Castro, RN, Jeanne Odom, RN, Michael R. Bishop, MD, Ronald E. Gress, MD, Frances T. Hakim, PhD

Blood (2004) 104 (11): 1249.

https://doi.org/10.1182/blood.V104.11.1249.1249

Published: 2004

Journal Articles

Comparison of Empiric Versus Prophylactic Administration of Ceftazidime during Neutropenia Associated with Reduced-Intensity Allogeneic Stem Cell Transplantation (RIST).

Kyle M. Donley, Juan C. Gea-Banacloche, MD, Robert M. Dean, MD, Seth M. Steinberg, PhD, Richard W. Childs, MD, Jeanne Odom, RN, Kathleen Castro, RN, Tracey Chinn, RN, Daniel H. Fowler, MD, Michael R. Bishop, MD

Blood (2004) 104 (11): 5100.

https://doi.org/10.1182/blood.V104.11.5100.5100

Published: 2004

Journal Articles

Immunotherapy and Chemotherapy Can Result in Long-Term Survival for Patients with Recurrent or Progressive Non-Hodgkin’s Lymphoma after Reduced-Intensity Allogeneic Stem Cell Transplantation.

Michael R. Bishop, MD, Robert M. Dean, MD, Wyndham H. Wilson, MD, PhD, Jeanne Odom, RN, Seth Steinberg, PhD, Michael Krumlauf, RN, Claude Kasten-Sportes, MD, Steven Z. Pavletic, MD, Kathleen Castro, RN, Tracey Chinn, RN, Ronald Gress, MD, Daniel H. Fowler, MD

Blood (2004) 104 (11): 1643.

https://doi.org/10.1182/blood.V104.11.1643.1643

Published: 2004

Journal Articles

Immunoablative Chemotherapy before Reduced-Intensity Allogeneic Stem Cell Transplantation: A Strategy to Provide Disease Control and to Enhance Early Graft-Versus-Lymphoma Effects.

Robert M. Dean, MD, Daniel H. Fowler, MD, Frances T. Hakim, PhD, Jeanne Odom, RN, Kathleen Castro, RN, Tracey Chinn, RN, Wyndham H. Wilson, MD, PhD, Ronald E. Gress, MD, Michael R. Bishop, MD

Blood (2004) 104 (11): 1829.

https://doi.org/10.1182/blood.V104.11.1829.1829

Published: 2004

Journal Articles

Engraftment Syndrome after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Graft-Versus-Host Disease Prophylaxis and T Cell Dose.

Robert M. Dean, MD, Kyle M. Donley, BA, Juan Gea-Banacloche, MD, Seth M. Steinberg, PhD, Jeanne Odom, RN, Michael Krumlauf, RN, Kathleen Castro, RN, Tracey Chinn, RN, Daniel H. Fowler, MD, Ronald E. Gress, MD, Michael R. Bishop, MD

Blood (2004) 104 (11): 5052.

https://doi.org/10.1182/blood.V104.11.5052.5052

Published: 2004

NARROW

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Targeted Lymphocyte Depletion: A Personalized Approach to Achieve Rapid Complete Donor Chimerism and Enhance Graft-Versus-Tumor Effects Following Reduced Intensity Allogeneic Stem Cell Transplantation for High-Risk Hematologic Malignancies.

Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment.

EPOCH-F: A Novel Salvage Regimen for Multiple Myeloma Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation

Burden of Illness in Chronic Graft vs. Host Disease - A Prospective Cohort Study.

Elevated Serum Interleukin-7 Levels Precede the Development of Acute Graft-Versus-Host Disease.

Safety and Efficacy of Cytotoxic Chemotherapy after Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Hematologic Malignancy.

Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).

Allograft T Cell Content Influences Early Engraftment after Reduced-Intensity Stem Cell Transplantation (RIST).

Increased Expression of Activating Receptors on NK Cells in the Post-Transplant Period.

Comparison of Empiric Versus Prophylactic Administration of Ceftazidime during Neutropenia Associated with Reduced-Intensity Allogeneic Stem Cell Transplantation (RIST).

Immunotherapy and Chemotherapy Can Result in Long-Term Survival for Patients with Recurrent or Progressive Non-Hodgkin’s Lymphoma after Reduced-Intensity Allogeneic Stem Cell Transplantation.

Immunoablative Chemotherapy before Reduced-Intensity Allogeneic Stem Cell Transplantation: A Strategy to Provide Disease Control and to Enhance Early Graft-Versus-Lymphoma Effects.

Engraftment Syndrome after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Graft-Versus-Host Disease Prophylaxis and T Cell Dose.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only